Elite Pharmaceuticals (ELTP) stock price, revenue, and financials

Elite Pharmaceuticals market cap is $65.6 m, and annual revenue was $17.99 m in FY 2020

$65.6 M

ELTP Mkt cap, 16-Oct-2020

$7.5 M

Elite Pharmaceuticals Revenue Q1, 2021
Elite Pharmaceuticals Gross profit (Q1, 2021)3 M
Elite Pharmaceuticals Gross profit margin (Q1, 2021), %39.5%
Elite Pharmaceuticals Net income (Q1, 2021)1.1 M
Elite Pharmaceuticals EBIT (Q1, 2021)830.6 K
Elite Pharmaceuticals Cash, 30-Jun-20202.8 M
Elite Pharmaceuticals EV65.3 M

Elite Pharmaceuticals Revenue

Elite Pharmaceuticals revenue was $17.99 m in FY, 2020

Embed Graph

Elite Pharmaceuticals Income Statement

Quarterly

USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

990.0k274.1k509.9k578.6k634.5k667.7k1.2m1.7m1.2m1.3m1.4m2.2m2.7m2.2m3.3m2.7m2.3m1.7m1.6m2.5m2.2m1.4m2.7m3.4m4.6m5.1m7.5m

Cost of goods sold

425.4k76.3k156.6k454.4k479.6k266.8k616.6k994.6k728.5k681.7k699.7k1.2m1.4m835.7k2.1m1.9m1.7m1.0m614.9k1.4m1.6m542.6k1.8m2.1m3.3m2.2m4.6m

Gross profit

564.6k197.8k353.3k124.2k154.9k400.9k542.3k698.7k433.2k574.7k663.2k966.1k1.3m1.4m1.1m834.9k603.9k687.7k1.0m1.1m591.3k820.5k922.8k1.3m1.3m2.9m3.0m

Gross profit Margin, %

57%72%69%21%24%60%47%41%37%46%49%45%48%62%34%31%26%40%62%44%27%60%34%39%29%57%39%

R&D expense

445.5k198.2k386.4k196.9k228.5k238.3k854.8k1.3m4.0m3.6m2.3m2.4m4.2m3.2m1.6m1.3m1.5m2.0m2.5m2.5m1.3m2.5m2.5m1.4m637.5k986.8k943.9k

General and administrative expense

324.6k476.9k288.4k365.0k401.2k381.0k272.6k494.5k626.6k740.6k625.1k754.4k881.6k654.8k699.0k667.0k694.3k856.0k594.1k615.0k882.8k614.9k748.2k681.5k798.6k878.5k868.8k

Operating expense total

901.1k789.4k784.3k610.0k670.2k675.1k1.2m1.9m4.9m4.6m3.2m3.4m5.3m4.1m2.4m2.0m2.3m2.9m3.1m3.2m2.4m3.5m3.6m2.4m1.8m2.2m2.1m

Depreciation and amortization

82.6k126.8k193.9k276.8k213.0k161.5k164.3k166.8k22.4k21.0k21.0k6.8k7.2k7.2k203.7k366.5k321.2k331.0k331.7k323.4k327.6k

EBIT

(336.5k)(591.6k)(430.9k)(485.8k)(515.3k)(274.2k)(686.6k)(1.2m)(4.4m)(4.1m)(2.6m)(2.4m)(4.0m)(2.7m)(1.2m)(1.2m)(1.7m)(2.2m)(2.1m)(2.1m)(1.9m)(2.7m)(2.6m)(1.1m)(454.5k)691.2k830.6k

EBIT margin, %

(34%)(216%)(85%)(84%)(81%)(41%)(59%)(73%)(381%)(323%)(188%)(111%)(149%)(124%)(38%)(45%)(74%)(131%)(131%)(81%)(86%)(195%)(98%)(34%)(10%)14%11%

Interest expense

57.4k57.9k57.1k58.5k61.2k63.9k8.9m175.3k29.5k25.4m23.6m7.1m2.1m9.5m

Interest income

3.1k3.1k3.2k4.0k4.4k4.5k1.3k1.6k1.7k3.0k5.3k2.3k276.0

Pre tax profit

(30.7m)13.9m8.8m(10.5m)1.1m9.4m(9.6m)(1.1m)(4.4m)21.4m21.0m1.1m4.2m(203.4k)(2.2m)1.8m(1.5m)(1.7m)(2.3m)279.7k(1.6m)(1.9m)130.9k

Income tax expense

2.5k3.0k1.0k2.5k(1.9m)3.0k(1.1m)(946.4k)

Net Income

(30.7m)13.9m8.8m(10.5m)1.0m9.4m(9.6m)(1.1m)(4.4m)21.4m21.0m4.7m(1.9m)(12.2m)1.1m4.2m1.7m(2.2m)1.8m(490.2k)(1.7m)(2.6m)(2.3m)279.7k(1.6m)(1.9m)1.1m

Elite Pharmaceuticals Balance Sheet

Quarterly

USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

1.8m1.3m568.7k475.1k207.3k65.7k766.2k1.1m8.2m7.6m8.3m11.6m9.0m8.1m12.8m12.6m13.3m9.6m7.6m7.2m5.6m4.7m3.7m2.6m2.3m1.9m2.8m

Accounts Receivable

513.5k252.7k483.3k497.9k562.9k526.4k636.0k1.0m1.2m1.1m1.7m1.0m1.4m747.0k1.2m1.1m544.7k721.2k1.1m1.2m1.1m1.0m660.4k998.9k2.0m2.6m4.4m

Prepaid Expenses

87.7k104.5k58.8k83.8k112.7k65.9k156.9k281.1k215.9k463.0k333.8k256.5k295.1k389.1k216.4k301.9k764.5k251.4k259.8k1.1m611.3k170.8k897.8k416.5k97.7k796.5k526.9k

Inventories

312.0k382.2k431.4k363.0k480.7k984.4k1.7m1.5m2.5m2.5m2.9m2.9m3.4m3.2m3.7m5.6m6.0m5.9m5.7m5.3m4.1m4.5m4.2m4.5m3.7m3.8m5.6m

Current Assets

2.7m2.1m1.5m1.4m1.4m1.6m3.3m3.9m12.1m11.7m13.2m15.8m14.1m12.4m18.0m19.7m20.6m16.4m14.6m14.8m11.5m10.4m9.4m8.5m8.1m9.0m13.3m

PP&E

4.2m4.2m4.2m4.2m4.2m4.1m3.9m4.1m4.9m5.2m5.5m7.0m7.6m7.7m8.2m8.4m8.7m9.3m9.3m9.1m8.9m8.8m8.8m8.1m7.8m7.5m7.1m

Total Assets

11.5m10.8m10.3m10.2m10.1m10.4m17.4m18.3m24.0m23.9m25.7m29.9m28.7m27.1m33.1m34.9m36.2m33.9m32.0m32.1m28.5m27.3m26.4m24.3m23.5m24.1m27.8m

Accounts Payable

1.1m937.3k1.2m1.3m1.1m1.4m1.9m2.0m3.2m2.7m3.2m2.5m3.6m3.0m1.5m2.3m1.4m880.7k860.1k1.4m1.1m1.1m2.3m2.1m1.7m986.0k2.1m

Short-term debt

783.1k

Current Liabilities

4.6m4.5m4.7m4.8m4.8m5.4m11.7m12.5m7.3m3.8m4.4m4.4m4.5m5.4m4.4m5.1m4.7m3.5m3.6m4.7m4.7m5.4m6.9m7.6m7.2m7.7m8.6m

Long-term debt

75.1k2.1m324.7k273.3k221.2k1.7m

Non-Current Liabilities

45.7m30.0m19.9m28.8m27.1m17.3m11.5m10.7m101.1m75.4m51.9m17.2m11.7m23.8m13.1m7.3m5.5m12.7m8.3m7.4m6.8m6.3m5.8m4.6m5.5m7.3m7.4m

Total Debt

75.1k2.1m324.7k273.3k221.2k2.5m

Total Liabilities

50.3m34.5m24.7m33.5m31.9m22.7m23.3m23.2m108.4m79.3m56.2m21.6m16.2m29.2m17.5m12.4m10.2m16.2m11.9m12.2m11.5m11.6m12.7m12.2m12.7m15.0m16.0m

Common Stock

243.4k254.8k264.8k346.2k349.7k350.3k494.8k513.2k568.0k591.8k609.0k660.0k681.8k688.2k731.0k893.7k911.2k780.8k786.0k788.8k804.7k817.0k820.5k829.0k832.9k834.0k841.1k

Preferred Stock

13.9m13.9m

Additional Paid-in Capital

106.8m108.0m108.6m117.0m117.5m117.6m131.1m133.1m144.7m152.4m156.2m116.7m116.2m90.3m110.3m159.2m161.1m144.3m144.9m145.2m146.8m148.1m148.4m149.1m149.5m149.6m150.3m

Retained Earnings

(145.6m)(131.7m)(122.9m)(140.4m)(139.4m)(130.0m)(137.1m)(138.2m)(229.4m)(208.0m)(187.0m)(137.2m)(136.9m)(151.2m)(141.6m)(137.3m)(135.7m)(141.0m)(139.2m)(139.7m)(144.2m)(146.8m)(149.1m)(151.5m)(153.1m)(155.0m)(153.0m)

Total Equity

(38.8m)(23.7m)(14.3m)(23.4m)(21.8m)(12.4m)(5.9m)(4.9m)(84.4m)(55.4m)(30.5m)(20.2m)(20.4m)(60.5m)(30.9m)22.5m26.0m3.8m6.2m6.0m3.1m1.8m(264.6k)(1.9m)(3.1m)9.1m11.8m

Financial Leverage

-0.3 x-0.5 x-0.7 x-0.4 x-0.5 x-0.8 x-3 x-3.7 x-0.3 x-0.4 x-0.8 x-1.5 x-1.4 x-0.4 x-1.1 x1.6 x1.4 x9 x5.2 x5.4 x9.2 x15.4 x-99.7 x-13 x-7.7 x2.7 x2.4 x

Elite Pharmaceuticals Cash Flow

Quarterly

USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(30.7m)(16.8m)(8.1m)(10.5m)(9.5m)(109.0k)(8.7m)(9.8m)(4.4m)17.0m38.0m4.7m6.9m(9.2m)1.1m5.3m7.0m(2.2m)(353.6k)(843.8k)(1.7m)(4.3m)(6.6m)279.7k(1.3m)(3.2m)1.1m

Depreciation and Amortization

124.9k244.8k363.5k118.4k236.1k330.5k222.3k334.3k209.4k435.5k648.5k161.5k325.8k492.6k176.1k345.4k504.9k188.1k412.7k706.8k303.7k530.7k941.8k331.0k662.6k993.1k327.6k

Accounts Receivable

(58.1k)319.0k88.4k(101.1k)(166.1k)(129.5k)29.2k(359.1k)(434.7k)(365.7k)(982.3k)397.8k147.7k816.6k310.1k384.8k985.6k212.9k(151.2k)(227.2k)(386.1k)(340.0k)15.4k323.0k(708.2k)(1.2m)(263.3k)

Inventories

(304.3k)234.1k185.0k(58.1k)(175.9k)(679.5k)(361.5k)(173.5k)(593.4k)(591.1k)(931.1k)168.8k(321.3k)(149.6k)(441.6k)(2.3m)(2.7m)525.7k707.1k1.1m757.8k412.1k705.6k(24.0k)783.5k705.3k(1.4m)

Accounts Payable

135.7k1.5k41.4k241.2k55.2k327.6k442.1k316.0k540.2k(183.6k)346.0k(2.1m)(960.1k)(1.5m)48.4k117.0k(434.9k)(685.0k)(571.1k)460.3k(1.4m)(834.6k)528.8k415.6k199.7k(402.8k)53.4k

Cash From Operating Activities

239.1k(230.3k)(789.1k)(297.4k)(1.1m)(1.5m)(1.3m)(2.7m)(4.2m)(8.6m)(11.2m)1.9m(1.6m)(3.4m)(764.2k)(3.1m)(3.8m)(1.1m)(3.3m)(3.8m)(1.7m)(3.4m)(4.7m)188.3k(275.5k)(587.7k)807.4k

Purchases of PP&E

(14.0k)

Capital Expenditures

(204.8k)(313.4k)(390.8k)(7.2k)(20.1k)(32.8k)(6.1k)(31.7k)(678.8k)(1.0m)(1.4m)(709.7k)(1.4m)(1.4m)(284.3k)(513.4k)(804.8k)(275.3k)(386.6k)(291.1k)(178.6k)(19.1k)(3.0k)(3.1k)(3.1k)

Cash From Investing Activities

(302.0k)(375.1k)(543.5k)(71.9k)(133.0k)(246.1k)(176.4k)(493.4k)4.2m3.9m3.5m(716.3k)(1.4m)(1.4m)(284.5k)(519.4k)(812.1k)(336.1k)(462.8k)(378.2k)(178.6k)(19.1k)(3.0k)(3.1k)(3.1k)37.3k

Short-term Borrowings

(3.5k)(6.3k)(9.6k)(1.7k)(3.4k)(5.1k)(11.5k)(65.0k)(133.4k)(90.9k)(148.6k)(281.2k)(185.1k)(290.2k)(160.5k)(345.4k)(516.5k)(90.0k)(90.0k)226.3k(95.0k)(95.0k)

Long-term Borrowings

(1.1m)(1.1m)(210.0k)(210.0k)(109.0k)(220.0k)(209.4k)

Cash From Financing Activities

(3.5k)118.7k75.4k176.0k811.8k1.1m1.9m3.9m1.2m5.5m9.1m3.0m4.6m5.4m2.4m4.7m6.4m405.4k742.2k823.5k354.2k917.5k1.2m114.0k260.8k188.7k811.4k

Net Change in Cash

(66.4k)(486.8k)(1.3m)(193.4k)(461.1k)(602.8k)397.2k711.8k1.2m685.3k1.3m4.2m1.6m639.1k1.3m1.1m1.8m(1.0m)(3.0m)(3.4m)(1.5m)(2.5m)(3.5m)299.3k(17.9k)(402.1k)1.7m

Interest Paid

423.0113.9k172.4k1.7k115.8k115.6k146.6k160.7k77.8k141.3k142.8k22.6k110.4k127.9k31.4k120.5k142.4k19.7k38.2k67.6k24.0k24.0k151.8k20.2k129.6k168.6k24.3k

Income Taxes Paid

2.5k2.5k2.5k3.0k4.0k4.0k2.3k

Free Cash Flow

34.3k(543.7k)(1.2m)(304.6k)(1.2m)(1.5m)(1.3m)(2.8m)(4.9m)(9.6m)(12.6m)1.2m(3.0m)(4.7m)(1.0m)(3.6m)(4.6m)(1.4m)(3.7m)(4.1m)(1.9m)(3.4m)(4.7m)185.3k(278.7k)(590.8k)

Elite Pharmaceuticals Ratios

USDQ1, 2012

Financial Leverage

-0.3 x